These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 22048556)

  • 41. Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review.
    Pasacreta JV
    Cancer Invest; 2003; 21(4):588-623. PubMed ID: 14533449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients.
    Claes E; Evers-Kiebooms G; Boogaerts A; Decruyenaere M; Denayer L; Legius E
    Am J Med Genet A; 2003 Jan; 116A(1):11-9. PubMed ID: 12476445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families.
    Biesecker BB; Ishibe N; Hadley DW; Giambarresi TR; Kase RG; Lerman C; Struewing JP
    Am J Med Genet; 2000 Aug; 93(4):257-63. PubMed ID: 10946349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.
    Levy DE; Garber JE; Shields AE
    J Gen Intern Med; 2009 Jul; 24(7):822-8. PubMed ID: 19455369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
    Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Psychometric characteristics of questionnaires designed to assess the knowledge, perceptions and practices of health care professionals with regards to alcoholic patients].
    Jaussent S; Labarère J; Boyer JP; François P
    Encephale; 2004; 30(5):437-46. PubMed ID: 15627048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
    Jeffers L; Morrison PJ; McCaughan E; Fitzsimons D
    Eur J Oncol Nurs; 2014 Aug; 18(4):411-8. PubMed ID: 24731853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychometric properties of the Decisional Conflict Scale in a sample of perinatal women with depressive symptoms: A study in Portugal and Norway.
    Lupattelli A; Branquinho M; Cardoso C; Tauqeer F; Bjørndal LD; Fonseca A
    Patient Educ Couns; 2024 Oct; 127():108337. PubMed ID: 38820986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Five families living with hereditary breast and ovarian cancer risk.
    Norris J; Spelic SS; Snyder C; Tinley S
    Clin J Oncol Nurs; 2009 Feb; 13(1):73-80. PubMed ID: 19193551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children.
    Tercyak KP; Peshkin BN; Demarco TA; Patenaude AF; Schneider KA; Garber JE; Valdimarsdottir HB; Schwartz MD
    Genet Test; 2007; 11(3):249-55. PubMed ID: 17949286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
    O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
    Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testing for hereditary breast and ovarian cancer in the southeastern United States.
    Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
    Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.
    Kim S; Aceti M; Baroutsou V; Bürki N; Caiata-Zufferey M; Cattaneo M; Chappuis PO; Ciorba FM; Graffeo-Galbiati R; Heinzelmann-Schwarz V; Jeong J; Jung MM; Kim SW; Kim J; Lim MC; Ming C; Monnerat C; Park HS; Park SH; Pedrazzani CA; Rabaglio M; Ryu JM; Saccilotto R; Wieser S; Zürrer-Härdi U; Katapodi MC
    JMIR Res Protoc; 2021 Jun; 10(6):e26264. PubMed ID: 34114954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast Cancer Screening Beliefs Questionnaire: Psychometric properties assessment of the Arabic version.
    Kwok C; Endrawes G; Lee CF
    Eur J Oncol Nurs; 2016 Feb; 20():42-8. PubMed ID: 26318141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer.
    Quinn GP; Vadaparampil ST; King LM; Miree CA; Friedman S
    Fam Cancer; 2009; 8(4):441-9. PubMed ID: 19554475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists.
    Bouhnik AD; N'Diaye K; Evans DG; Harris H; Tibben A; van Asperen C; Schmidtke J; Nippert I; Mancini J; Julian-Reynier C
    PLoS One; 2017; 12(6):e0178447. PubMed ID: 28570656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    Garcia C; Sullivan MW; Lothamer H; Harrison KM; Chatfield L; Thomas MH; Modesitt SC
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1835-1841. PubMed ID: 32656916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.